Ovarian Cancer

Aggressive Treatment Might Benefit Older Patients With Ovarian Cancer

January 15th 2021, 10:30pm

Article

Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.

Payer Coverage Is the Key to Cost-effective Panel Testing in Gynecological Cancers

January 15th 2021, 5:00pm

Article

Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company.

What Is Clinical Utility in a Tumor Biomarker Test? Former ASCO President Knows It When He Sees It

January 9th 2021, 9:15pm

Article

Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.

Study Finds Link Between Larger Endometriomas and Ovarian Cancer

January 9th 2021, 1:00am

Article

A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.

Dr Bradley Monk Discusses Indications for PARP Inhibitors in Ovarian Cancer

December 30th 2020, 4:30pm

Video

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, describes the current indications for PARP inhibitors in ovarian cancer.

Dr Bradley Monk on Response to PARP Inhibitors in Ovarian Cancer

December 28th 2020, 3:00pm

Video

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.

Dr Bradley Monk on the Changing Regulatory Landscape of PARP Inhibitors

December 26th 2020, 2:30pm

Video

Bradley Monk, MD, FACOG, FACS, a professor at the University of Arizona, chronicles the regulatory changes in PARP inhibitors as they gain more indications in ovarian cancer.

Dr Bradley Monk on Multidisciplinary Care With PARP Inhibitors

December 24th 2020, 4:00pm

Video

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, shares his experience mitigating the potential side effects of PARP inhibitors in ovarian cancer treatment.

Dr Bradley Monk Discusses PARP Inhibitor Reimbursement

December 18th 2020, 6:30pm

Video

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.

Proximity to Treatment, Racial Disparities Seen in Ovarian Cancer Survival

December 16th 2020, 7:30pm

Article

Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.